Skip to main content
Premium Trial:

Request an Annual Quote

NIH RADx Program Awards Autonomous Medical Devices Incorporated $5.2M in Phase 2 Funding

NEW YORK – The Rapid Acceleration of Diagnostics Technology program (RADx Tech) at the National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering has awarded Autonomous Medical Devices Incorporated (AMDI) $5.2 million in additional Phase 2 funding to further develop its rapid diagnostic system and a panel for respiratory infections.

Santa Ana, California-based AMDI will use the funds to finalize development of its Fast PCR System, a 10-minute RT-PCR instrument that can detect as many as 32 targets per sample. 

The funding will also be deployed to complete the first syndromic panel for the system, which will detect respiratory viruses such as influenza A and B, respiratory syncytial virus, and SARS-CoV-2, the firm said in a statement.

RADx Tech previously awarded AMDI $1.2 million to develop its Fast PCR System.

"AMDI is grateful for the recognition by the NIBIB for a second award that gives us the opportunity to complete the development of the Fast PCR System," AMDI CEO David Okrongly said in a statement.

AMDI's core technology includes sample preparation using hyperbaric heating and ultrafast PCR chemistry in a disc format.

"Combining HBH with our ultrafast thermal cycling allows us to stay under 10 minutes regardless of the number of targets we put on the test disc," Regis Peytavi, chief technology officer at AMDI, said in a statement.

Earlier this month, RADx Tech awarded $4.4 million in additional Phase 2 funding to Maxim Bio for its battery-powered FiarFly reader and a multiplex test to detect flu A/B and SARS-CoV-2. RADx Tech had previously awarded Maxim Bio $5.3 million in Phase 2 funding for a COVID-19 lateral flow immunoassay.

In 2023, RADx Tech awarded diagnostics development funding to Sapphiros, DiagMetrics, 3EO Health, Sensible Diagnostics, Domus Diagnostics, C2Sense and Princeton BioMeditech, and AmplifiDx.